<DOC>
	<DOCNO>NCT00626600</DOCNO>
	<brief_summary>Assessing safety tolerability Oxycodone Hydrochloride 50mg/mL subject severe cancer pain .</brief_summary>
	<brief_title>A Study Assess Safety Tolerability Oxycodone Hydrochloride 50mg/mL Administered Infusion</brief_title>
	<detailed_description>This study involve treatment phase 20 day . During time patient receive Oxycodone Hydrochloride 50mg/ml subcutaneous infusion . During treatment phase , safety assess documentation type frequency spontaneously report adverse event adverse event note assessment infusion site ( every 24 hour resited ) . The subject follow 7 day collect information ongoing AEs/SAEs new AEs/SAEs may occur .</detailed_description>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>Inclusion Criteria 1 . Male female subject age 18 year , severe cancer pain . 2 . Subjects require strong opioid subcutaneous infusion stabilise manage cancer pain effectively . 3 . Subjects give write informed consent participate study . 4 . Subjects agree primary care physician inform participation study . 5 . Subjects consent process trial data accord requirement UK Data Protection Act 1998 . Exclusion Criteria 1 . Subjects pregnant , lactate Investigators opinion risk conceive use adequate contraception measure . 2 . Subjects know hypersensitivity ( allergic reaction ) oxycodone , opioids excipients . 3 . Subjects plan receive chemotherapy study treatment period currently receive continuous i.v . chemotherapy infusion . 4 . Subjects neutropenia , thrombocytopenia coagulation disorder . 5 . Subjects contraindication oxycodone outline Investigator Brochure Summary Product Information sheet oxycodone . 6 . Subjects currently participate another clinical research study involve new chemical entity . 7 . Subjects Investigator believe medically unfit receive study medication , unsuitable reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Oxycodone Hydrochloride 50mg/mL</keyword>
	<keyword>Observational</keyword>
	<keyword>Infusion</keyword>
	<keyword>Severe cancer pain</keyword>
</DOC>